Great Point Partners’s Palisade Bio PALI Stock Holding History

Great Point Partners’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.96M	Buy	+3,405,757	New	+$6.19M	1.37%	26

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Great Point Partners's PALI Position: Q1 2026 in Review

Great Point Partners opened a new position in Palisade Bio (PALI) in Q1 2026: 3,405,757 shares worth $5.96M. The stake represents 1.37% of the portfolio and ranks #26 among its holdings.

96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

Great Point Partners held 3,405,757 shares of Palisade Bio worth $5.96M as of Q1 2026.
Palisade Bio was a new Great Point Partners position in Q1 2026.
Palisade Bio made up 1.37% of Great Point Partners's portfolio in Q1 2026, its #26 holding.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.